Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996

This article was originally published in The Gray Sheet

Executive Summary

SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996 is planned by the Bothell, Washington-based company, CEO Steven Quay, MD/PhD, told a Medical Investments Northwest conference in Seattle Sept. 12. A total of 45 patients of a planned 120 have completed Phase II trials, which began July 10. Initial indications will be diagnosis of cardiovascular disease, renal vascular disease/hypertension, and cancer, Quay said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002828

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel